Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium

CNS Drugs

Volumn 26, Issue 4, 2012, Pages 337-350

  Simoens, Steven ^a   De Naeyer, Liesbet ^b   Dedeken, Peter ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UCB PHARMA   (Belgium)

Author keywords

Cost effectiveness; Epilepsy; Lacosamide; Partial epilepsies.

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADJUVANT THERAPY; ADULT; ARTICLE; BELGIUM; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REFRACTORY PERIOD; SENSITIVITY ANALYSIS; STANDARD; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ANTICONVULSANTS; BELGIUM; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84859033095     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11599240-000000000-00000     Document Type: Article

References (26)

1. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-2 (Pubitemid 40470667)
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-85
3. Hauser W. Epilepsy: frequency, causes, and consequences. New York (NY): Demos Press, 1990
4. Kotsopoulos IA, van Merode T, Kessels FG, et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43 (11): 1402-9 (Pubitemid 35365000)
5. Hitiris N, Mohanraj R, Norrie J, et al. Mortality in epilepsy. Epilepsy Behav 2007; 10 (3): 363-76 (Pubitemid 46577939)
6. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718-79
7. King Jr JT, Sperling MR, Justice AC, et al. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg 1997; 87 (1): 20-8 (Pubitemid 27271022)
8. Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia 1997; 38 (2): 154-63 (Pubitemid 27093326)
9. Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: cost-effectiveness in refractory epilepsy. Clin Drug Investig 2003; 23 (4): 225-32 (Pubitemid 36469960)
10. Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53 (6): 421-7 (Pubitemid 28154742)
11. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005; 9 (15): 1-186
12. Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008; 26: 463-76 (Pubitemid 351704857)
13. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-77
14. Birbeck GL, Hays RD, Cui X, et al. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002; 43 (5): 535-8 (Pubitemid 34533711)
15. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62: 375-81 (Pubitemid 350105951)
16. Leppik I, Morrell M, Godfroid P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia 2003; 44 (10): 1350-2 (Pubitemid 37280380)
17. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48 (7): 1308-17 (Pubitemid 47063096)
18. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51 (6): 958-67
19. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50 (3): 443-53
20. National Institute for Health and Clinical Excellence. Newer drugs for epilepsy in adults. London: National Institute for Health and Clinical Excellence, 2004
21. Schiller Y, Najjar Y. Quantifying the response to anti-epileptic drugs: effect of past treatment history. Neurology 2008; 70 (1): 54-65
22. Rosenfeld W, Rosenow F, Isojarvi J, et al. Long-term safety and tolerability of lacosamide for partial-onset seizures: an interim evaluation of patients exposed to lacosamide in double-blind and open-label trials. Epilepsia 2009; 50 Suppl. 11: 453
23. National Institute for Health and Disability Insurance. List of health care services. Brussels: National Institute for Health and Disability Insurance, 2010
24. Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmaco-economic evaluations in Belgium. Brussels: Federaal Kenniscentrum voor de Gezondheidszorg, 2008
25. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001: 172-214
26. Wehner T, Bauer S, Hamer HM, et al. Six months of post-marketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16: 423-5